RU2013123796A - Способ лечения болезни дюпюитрена - Google Patents
Способ лечения болезни дюпюитрена Download PDFInfo
- Publication number
- RU2013123796A RU2013123796A RU2013123796/15A RU2013123796A RU2013123796A RU 2013123796 A RU2013123796 A RU 2013123796A RU 2013123796/15 A RU2013123796/15 A RU 2013123796/15A RU 2013123796 A RU2013123796 A RU 2013123796A RU 2013123796 A RU2013123796 A RU 2013123796A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- fibro
- musculoskeletal
- disease
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1018325.9A GB201018325D0 (en) | 2010-10-30 | 2010-10-30 | Treatment for dupuytren's disease |
| GB1018325.9 | 2010-10-30 | ||
| GBGB1018362.2A GB201018362D0 (en) | 2010-11-01 | 2010-11-01 | Treatment of dupuytren's disease |
| GB1018362.2 | 2010-11-01 | ||
| GB1113718.9 | 2011-08-10 | ||
| GBGB1113718.9A GB201113718D0 (en) | 2011-08-10 | 2011-08-10 | Treatment of Dupuytren's Disease |
| PCT/EP2011/069147 WO2012056044A1 (en) | 2010-10-30 | 2011-10-31 | Treatment for dupuytren's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013123796A true RU2013123796A (ru) | 2014-12-10 |
Family
ID=44913268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013123796/15A RU2013123796A (ru) | 2010-10-30 | 2011-10-31 | Способ лечения болезни дюпюитрена |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9138458B2 (enExample) |
| EP (1) | EP2632446B1 (enExample) |
| JP (2) | JP6004494B2 (enExample) |
| AU (2) | AU2011322482B2 (enExample) |
| CA (1) | CA2847197C (enExample) |
| DK (1) | DK2632446T3 (enExample) |
| ES (1) | ES2715204T3 (enExample) |
| RU (1) | RU2013123796A (enExample) |
| WO (1) | WO2012056044A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2715204T3 (es) | 2010-10-30 | 2019-06-03 | Univ Oxford Innovation Ltd | Tratamiento de la enfermedad de Dupuytren |
| CA2872227A1 (en) | 2012-05-01 | 2013-11-07 | Proteolease Ltd. | Methods for extracting a tooth |
| EP2847215A1 (en) * | 2012-05-07 | 2015-03-18 | Synthes GmbH | Methods and devices for treating intervertebral disc disease |
| EP3019017A4 (en) * | 2013-07-11 | 2017-09-27 | 180 Therapeutics LP | Method of treating fibroproliferative disorders including dupuytren ' s disease with one or more specific human matrix metalloproteinase and a tnf antagonist |
| HK1247622A1 (zh) * | 2015-03-02 | 2018-09-28 | 180 Therapeutics Lp | 利用il-33拮抗剂来治疗局部纤维化的方法 |
| EP3439701A4 (en) * | 2016-04-08 | 2019-12-11 | 180 Therapeutics LP | METHOD FOR THE TREATMENT OF DUPUYTRIAL DISEASE IN EARLY STAGE |
| WO2018045213A1 (en) * | 2016-09-02 | 2018-03-08 | 180 Therapeutics Lp | Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody |
| EP3570865A4 (en) * | 2016-09-02 | 2020-05-20 | 180 Therapeutics LP | METHOD FOR TREATING A LOCALIZED FIBROTIC DISEASE USING A BISPECIFIC IL-33 / TNF ANTIBODY |
| US11564963B2 (en) | 2017-11-22 | 2023-01-31 | Progeneron, Llc | Topical compositions, process of large-scale manufacture, and method of use |
| EP3980022B1 (en) | 2019-06-07 | 2025-01-15 | Dale Biotech, LLC | Treatment of dupuytren's disease, osteoarthritis, or adhesive capsulitis with rhamnolipids. |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59010908D1 (de) * | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
| US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
| GB9405076D0 (en) * | 1994-03-16 | 1994-04-27 | Inst Of Ophtalmology | A medical use of matrix metalloproteinase inhibitors |
| US6486140B2 (en) * | 1994-07-19 | 2002-11-26 | Medicarb Ab | Agents, and methods employing them, for the prevention or reduction of tissue adhesion at a wound site |
| US5589171A (en) | 1994-08-22 | 1996-12-31 | Advance Biofactures Of Curacao | Treatment of Dupuytren's disease with collagenase |
| US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| CN1083337C (zh) | 1996-03-26 | 2002-04-24 | 精工爱普生株式会社 | 打印装置及其控制方法 |
| US6086872A (en) * | 1997-03-27 | 2000-07-11 | Advance Biofactures Of Curacao, Nv | Amelioration of dupuytren's disease |
| US6031005A (en) * | 1998-08-03 | 2000-02-29 | Easterling; W. Jerry | Composition and method for treating Peyronie's disease and related connective tissue disorders |
| US6060474A (en) * | 1998-11-05 | 2000-05-09 | New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Method for preventing scar tissue formation |
| GB0105330D0 (en) | 2001-03-02 | 2001-04-18 | Renovo Ltd | Genetic testing |
| US7754217B2 (en) | 2001-03-16 | 2010-07-13 | Bio3 Research Srl | HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
| WO2002087576A1 (en) * | 2001-04-30 | 2002-11-07 | Arachnova Therapeutics Ltd. | The treatment of scarring and related conditions using ppar-gamma activators |
| DE60327075D1 (de) | 2002-07-05 | 2009-05-20 | Univ Laval | Der entzündungsreaktionen |
| GB0306165D0 (en) | 2003-03-18 | 2003-04-23 | Delta G Ltd | Medical treatment |
| US20080025986A1 (en) * | 2003-06-06 | 2008-01-31 | Ozes Osman N | Methods of Treating Tnf-Mediated Disorders |
| US20050186261A1 (en) * | 2004-01-30 | 2005-08-25 | Angiotech International Ag | Compositions and methods for treating contracture |
| CA2593038C (en) * | 2005-01-21 | 2015-03-17 | Advance Biofactures Corporation | Methods for treating adhesive capsulitis |
| US7431927B2 (en) * | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
| EP2403353B1 (en) | 2009-03-06 | 2019-08-14 | Kenneth William Gregg | Composition for controlling fish |
| US20110229451A2 (en) | 2009-03-06 | 2011-09-22 | Halozyme, Inc. | Temperature sensitive mutants of matrix metalloproteases and uses thereof |
| ES2715204T3 (es) * | 2010-10-30 | 2019-06-03 | Univ Oxford Innovation Ltd | Tratamiento de la enfermedad de Dupuytren |
-
2011
- 2011-10-31 ES ES11779628T patent/ES2715204T3/es active Active
- 2011-10-31 CA CA2847197A patent/CA2847197C/en active Active
- 2011-10-31 DK DK11779628.4T patent/DK2632446T3/en active
- 2011-10-31 EP EP11779628.4A patent/EP2632446B1/en active Active
- 2011-10-31 AU AU2011322482A patent/AU2011322482B2/en active Active
- 2011-10-31 WO PCT/EP2011/069147 patent/WO2012056044A1/en not_active Ceased
- 2011-10-31 JP JP2013535462A patent/JP6004494B2/ja active Active
- 2011-10-31 US US13/882,262 patent/US9138458B2/en active Active
- 2011-10-31 RU RU2013123796/15A patent/RU2013123796A/ru not_active Application Discontinuation
-
2015
- 2015-09-11 US US14/852,442 patent/US10273296B2/en active Active
-
2016
- 2016-08-29 JP JP2016166524A patent/JP2017014266A/ja active Pending
-
2017
- 2017-06-23 AU AU2017204267A patent/AU2017204267B2/en active Active
-
2019
- 2019-04-30 US US16/399,547 patent/US10669334B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2632446A1 (en) | 2013-09-04 |
| US9138458B2 (en) | 2015-09-22 |
| CA2847197C (en) | 2020-11-03 |
| AU2011322482B2 (en) | 2017-03-23 |
| JP2013540803A (ja) | 2013-11-07 |
| DK2632446T3 (en) | 2019-04-01 |
| US20160280775A1 (en) | 2016-09-29 |
| US20190322733A1 (en) | 2019-10-24 |
| US20130287760A1 (en) | 2013-10-31 |
| US10669334B2 (en) | 2020-06-02 |
| US10273296B2 (en) | 2019-04-30 |
| CA2847197A1 (en) | 2012-05-03 |
| JP2017014266A (ja) | 2017-01-19 |
| EP2632446B1 (en) | 2018-12-12 |
| JP6004494B2 (ja) | 2016-10-12 |
| AU2017204267A1 (en) | 2017-07-13 |
| AU2017204267B2 (en) | 2019-05-23 |
| AU2011322482A1 (en) | 2013-05-23 |
| WO2012056044A1 (en) | 2012-05-03 |
| ES2715204T3 (es) | 2019-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| RU2015107877A (ru) | Способы лечения болезни альцгеймера и фармацевтические композиции | |
| EA201790406A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
| JP2013540803A5 (enExample) | ||
| EA201500293A1 (ru) | Антихолинэргическая нейропротективная композиция и способы | |
| MA37829A1 (fr) | Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha | |
| EA201000365A1 (ru) | Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза | |
| BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
| EA201391468A1 (ru) | 1,3-оксазины в качестве ингибиторов bace1 и/или bace2 | |
| AR055038A1 (es) | Metodo y compuesto para tratar enfermedades vasculares perifericas | |
| EA200971053A1 (ru) | Способы лечения кожных язв | |
| EA201071038A1 (ru) | Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| EA201071043A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1 | |
| ATE470151T1 (de) | Diagnose, behandlung und prävention von gefässerkrankungen mittels il-1alpha- autoantikörpern | |
| MA37763B1 (fr) | Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1 | |
| ATE525084T1 (de) | Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus | |
| Webster et al. | Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain | |
| EA201300314A1 (ru) | Композиции и лекарственное средство для лечения глазных болезней, устройство, содержащее композиции и лекарственное средство | |
| EP2545929A4 (en) | Means for the alleviation or cure of chronic prostatitis, interstitial cystitis or bladder-weaning disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20161220 |